Convé plc (Convé), the specialty pharmaceutical company, is pleased to announce the appointment of Dr David Glover (MRCP FFPM) as a Non-Executive Director of the Company.
David is a very experienced physician and senior manager with over 20 years experience of clinical development and research in pharmaceutical and biotechnology companies. He held senior positions with Merck Sharp and Dohme and Schering Plough before joining Cambridge Antibody Technology (CAT) Group plc initially as Medical Director.
In his ten year career with CAT he progressed to become Chief Medical Officer and Executive Director. At CAT David played a major role in helping the company to raise over £180 million through private and public raisings.
David’s pharmaceutical industry experience spans all phases of preclinical and clinical development programs, on many different chemical and biological drugs in many therapeutic areas, through to regulatory approvals, right through to product launches and ongoing medical-marketing support.
John Dawson, CEO of Convé, commented:
“I am delighted that David has joined the board of Convé. David’s extensive experience of developing products through research, clinical development and regulatory approval, will be invaluable as we progress our clinical development program.”
For further information, please contact:
John Dawson, Managing DirectorPeter Banks, Finance DirectorCONVÉ PLC Tel No: + 44 (0)870 048 0250 Tim Anderson/Lisa Baderoon/Rebecca Skye DietrichBUCHANAN COMMUNICATIONS Tel No: + 44 (0) 20 7466 5000
Note to Editors: Convé is a speciality pharmaceutical company that develops and commercialises its patented copper silicate technology for dermal and mucosal applications. Its lead technology is Q-Sil™ which focuses on the treatment of onychomycosis (nail fungus). Onychomoycosis affects 15% of the population, however only 5% of the infected population are treated, largely as a result of safety and efficacy concerns with current treatments on the market. The current market for this ailment is in the region of US$1.5 billion.
Convé has developed a unique soluble silicate delivery technology, which enhances the activity of copper by delivering the metallic element in a formulation that provides slow release and better persistence at site of application.
